Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha n3 - AIM ImmunoTech

Next Previous
X
Search
Drug Profile

Interferon alpha n3 - AIM ImmunoTech

Alternative Names: Alferon LDO; Alferon LDO (Low Dose Oral); Alferon N; Alferon N Gel; Alferon N Injection; Alferon N LDO; alpha-n3-IF; Altemol; Interferon alfa-N3; Interferon alfa-n3 human leukocyte derived (Alferon N Injection); Interferon-α-n3; Leukocyte interferon; Naturaferon; Natural alpha interferon

Latest Information Update: 28 Feb 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stem Cell Innovations
  • Developer AIM ImmunoTech; Fujimoto Pharmaceutical; Howard University; National Institute of Allergy and Infectious Diseases; Swiss Department of Defence, Civil Protection and Sport; United States Army Medical Research Institute of Infectious Diseases
  • Class Anti-inflammatories; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Middle East respiratory syndrome coronavirus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Human papillomavirus infections
  • Registered Hepatitis C; Inflammation; Multiple sclerosis; Viral infections
  • Preclinical Influenza A virus H7N9 subtype
  • No development reported Ebola virus infections; HIV infections; Influenza A virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Venezuelan equine encephalomyelitis; West Nile virus infections
  • Discontinued Kaposi's sarcoma; Small cell lung cancer; Zika virus infection

Most Recent Events

  • 01 Feb 2023 Preclinical development is ongoing in Zika-virus-infection in USA (AIM ImmunoTech pipeline, February 2023)
  • 01 Feb 2023 Discontinued - Preclinical for Influenza A virus H7N9 subtype in Switzerland (SC)
  • 01 Feb 2023 Discontinued - Preclinical for Zika virus infection in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top